<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02675023</url>
  </required_header>
  <id_info>
    <org_study_id>911501</org_study_id>
    <nct_id>NCT02675023</nct_id>
  </id_info>
  <brief_title>Assessment of Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects</brief_title>
  <official_title>A Randomized, Open-label, Two-arm, Parallel Group, Single Dose Study to Assess the Pharmacokinetics and Safety of M923 Administered Via Auto-injector or Prefilled Syringe, in Healthy Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Momenta Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Momenta Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      This study will assess the pharmacokinetic (PK) and safety of a single 0.8 mL (40 mg)
      subcutaneous (SC) dose of M923 administered via an auto-injector (AI) or a prefilled syringe
      (PFS) in healthy subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve from 0 to infinity</measure>
    <time_frame>Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71</time_frame>
    <description>Area under the concentration-time curve in serum from time zero (predose) extrapolated to infinity [AUC(0-inf)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve from 0 to 336 hours</measure>
    <time_frame>Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, and 15</time_frame>
    <description>Area under the concentration-time curve in serum from time zero (predose) to 336 hours postdose [AUC(0-336)]</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics: Maximum concentration in serum (Cmax)</measure>
    <time_frame>Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Serum M923 concentration up to Day 71</measure>
    <time_frame>Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve in serum from time zero (predose) to 1200 hours postdose [AUC(0-1200)]</measure>
    <time_frame>Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, and 50</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve in serum from time zero (predose) to time of the last quantifiable concentration [AUC(0-last)]</measure>
    <time_frame>Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Time of maximum concentration in serum [tmax]</measure>
    <time_frame>Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71</time_frame>
    <description>Obtained directly from the observed concentration versus time data</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Terminal rate constant (λ z)</measure>
    <time_frame>Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Terminal half-life (t½)</measure>
    <time_frame>Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Apparent volume of distribution (Vz/F)</measure>
    <time_frame>Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Apparent systemic clearance after extravascular dosing (CL/F)</measure>
    <time_frame>Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the concentration-time curve extrapolated from time &quot;t&quot; to infinity [% AUCex]</measure>
    <time_frame>Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area under the serum concentration-time curves from time zero (predose) to time &quot;t&quot; [AUC(0-t)] by which &gt;20.0% of participants have developed neutralizing antidrug antibody [nADA]</measure>
    <time_frame>Within 90 minutes pre-dose; and post-dose at 8 hours, and Day 2, 3, 4, 5, 6, 7, 9, 11, 15, 22, 29, 40, 50, and 71</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-serious and serious adverse events (SAEs)</measure>
    <time_frame>Throughout the study period of approximately 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of injection site reactions</measure>
    <time_frame>Throughout the study period of approximately 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in Vital signs</measure>
    <time_frame>Throughout the study period of approximately 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with new clinically significant findings from the physical examination</measure>
    <time_frame>Throughout the study period of approximately 8 months</time_frame>
    <description>Physical examination will be done on the following body systems: general appearance, head and neck, eyes and ears, nose and throat, chest, lungs, heart, abdomen, extremities and joints, lymph nodes, skin, and neurological.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in Twelve-lead electrocardiogram (ECG)</measure>
    <time_frame>Throughout the study period of approximately 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in laboratory results</measure>
    <time_frame>Throughout the study period of approximately 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in clinical chemistry</measure>
    <time_frame>Throughout the study period of approximately 8 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinically significant changes in urinalysis</measure>
    <time_frame>Throughout the study period of approximately 8 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">603</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Auto-injector (AI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M923 administered via AI</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prefilled syringe (PFS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>M923 administered via PFS</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M923</intervention_name>
    <description>Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)</description>
    <arm_group_label>Prefilled syringe (PFS)</arm_group_label>
    <arm_group_label>Auto-injector (AI)</arm_group_label>
    <other_name>Adalimumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy male and female participants aged 18 to 55 years, inclusive

          2. Healthy participants as determined by pre-study medical history, physical examination,
             vital signs and 12-lead electrocardiogram (ECG)

          3. Participants with clinical laboratory test results that are not clinically significant
             and are acceptable to the investigator at screening and admission to the study site
             (Day -1)

          4. Participants with a body weight between 60.0 kg and 100.0 kg and a body mass index
             between 18.5 kg/m2 and 34.9 kg/m2, inclusive

          5. Healthy male participants must be willing to comply with the contraception
             restrictions for this study.

             -Male participants with non-pregnant female partners of childbearing potential should
             avoid conception of a child during the study (up to Day 71 post-dose) and for 90 days
             thereafter.

          6. Healthy female participants must have a negative pregnancy test at screening and on
             admission to the study site (Day -1), must not be lactating and must be using an
             acceptable method of contraception throughout the study and for 30 days after study
             completion, or be of non-childbearing potential.

             -Non-pregnant female partners of male participants who are of childbearing potential
             should use an effective form of contraception.

          7. Participants who have smoked ≤10 cigarettes or 3 cigars or 3 pipes/day for at least 3
             months prior to screening and are willing to comply with smoking restrictions during
             residency at the study site

          8. Participants who are able to understand and provide written informed consent including
             signature on an informed consent form (ICF) approved by an Ethics Committee (EC)/
             Institutional Review Board (IRB)

          9. Participants who have provided written authorization for use and disclosure of
             protected health information

         10. Participants who agree to abide by the study schedule and dietary restrictions and to
             return for the required assessments

        Exclusion Criteria:

          1. History and/or current presence of clinically significant angioedema, or eczematous
             dermatitis that requires prescription medication, clinically significant
             hypersensitivity, or severe allergic reactions (either spontaneous or following IP
             administration), also including known or suspected clinically relevant drug
             hypersensitivity to any components of the IP or comparable drugs, including latex

          2. Active or latent tuberculosis or who have a history of TB.

          3. History of invasive and/or active systemic fungal infections or other severe
             opportunistic infections, including recurrent or clinically significant chronic local
             fungal infections

          4. A serious infection within 6 months prior to investigational product (IP)
             administration and/or an infection within 2 weeks of screening or during the screening
             period unless resolved completely within 2 weeks of admission to the study site on Day
             -1

          5. Herpes zoster infection in the last year or more than 2 herpes zoster infections in
             his/her lifetime

          6. Frequent chronic or recurrent infections (defined as &gt;3 a year requiring prescribed
             treatment)

          7. Previous use of adalimumab, HUMIRA®, or another recombinant human monoclonal antibody

          8. Intake of any investigational drug in another study within 30 days (or 5 half-lives,
             whichever is greater) prior to intake of IP in this study or have received the last
             dose of a study drug more than 30 days ago (or 5 half-lives, whichever is greater) but
             who are on extended follow-up, or planned intake of an investigational drug (other
             than for this study) during the course of this study

          9. History of alcohol abuse in the year preceding the screening visit, or history of
             excess alcohol consumption.

         10. Known history of opioid or cocaine drug abuse or any other drug abuse in the past year
             or positive tests for drugs of abuse or alcohol at screening or admission to the study
             site (Day -1)

         11. Donation of blood or blood products (eg, plasma, platelets) within 30 days prior to IP
             administration

         12. Use of any prescribed or non-prescribed medication including antacids, analgesics
             (other than paracetamol/acetaminophen), dietary supplements or herbal medication
             during the 2 weeks prior to IP administration or longer if the medication has a long
             half-life. Use of any medication deemed necessary by the participant's physician to
             treat or prevent any medical condition, paracetamol/acetaminophen ≤3 g/day and use of
             vitamins at daily recommended doses is allowed; for female volunteers, oral birth
             control and hormone replacement therapy is allowed

         13. History of or existing congestive heart failure

         14. History of or existing signs or symptoms of demyelinating disease such as optic
             neuritis and/or multiple sclerosis

         15. History of any cancer including lymphoma, leukemia, skin cancer or cervical carcinoma
             in situ

         16. Impaired liver function

         17. History of immunodeficiency (including those participants with a positive test for
             human immunodeficiency virus [HIV] I and II at screening) or other clinically
             significant immunological disorders, or auto-immune disorders, (eg, rheumatoid
             arthritis, lupus erythematosus, scleroderma, psoriasis)

         18. Positive test for anti-citrullinated protein antibodies at screening

         19. Clinically relevant history or presence of respiratory, gastrointestinal, renal,
             hepatic, hematological (including pancytopenia, aplastic anemia, or blood dyscrasia),
             metabolic (including known diabetes mellitus), lymphatic, neurological,
             cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological,
             dermatological, connective tissue diseases or disorders as judged by the investigator

         20. Received a live vaccine within 12 weeks prior to admission to the study site (Day -1)
             or plan to receive a live vaccine during the study (up to and including Day 71)

         21. Volunteers who are vegans or have medical dietary restrictions

         22. Volunteers who cannot communicate reliably with the investigator

         23. Volunteer is a family member or employee of the investigator or study site staff or
             study team
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Caminis, MD</last_name>
    <role>Study Director</role>
    <affiliation>Shire</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>QOPK Phase 1 Clinic</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <zip>66211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QLON Phase 1 Clinic</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 22, 2016</study_first_submitted>
  <study_first_submitted_qc>February 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2016</study_first_posted>
  <last_update_submitted>April 19, 2017</last_update_submitted>
  <last_update_submitted_qc>April 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

